Skip to contentB
BridgeBio Pharma, Inc.
B
BBIOBridgeBio Pharma, Inc. Q1 2025 · 10-Q
Revenue$116.63M$116.63M−44.8% vs Q1 2024 Net Income-$169.61M-$169.61MN/M vs Q1 2024 EPS Diluted-$0.88-$0.88N/M vs Q1 2024 Operating Income-$104,372,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BridgeBio Pharma, Inc. · CIK 1743881 · Engraved from SEC EDGAR
Free Cash Flowderived-$199,235,000N/M Margins · derivedOperating margin-89.5%−89.7 pt vs Q1 2024
Net margin-145.4%−128.3 pt vs Q1 2024
ended Mar 31, 2025 · filed Apr 29, 2025 · 29 d after period end